Advertisement

Clinical Rheumatology

, Volume 3, Supplement 1, pp 39–50 | Cite as

Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis Cooperative systematic studies of rheumatic diseases

  • H. J. Williams
  • J. R. Ward
  • M. J. Egger
  • J. C. Reading
  • C. O. Samuelson
  • M. Altz-Smith
  • R. W. Willkens
  • M. A. Solsky
  • S. P. Hayes
  • D. Furst
  • A. Weinstein
  • R. F. Meenan
  • M. Guttadauria
  • S. B. Kaplan
  • J. Klippel
Article

Summary

Two hundred eight patients were studied in a prospective, controlled, double-blind multicenter trial comparing auranofin (AUR), gold sodium thiomalate (GST), and placebo. One hundred sixty-one patients completed at least 20 weeks of therapy. Response to a variety of measures of efficacy was generally modest for both gold treatment groups although improvement was continuing in both groups at the end of the study. There was statistically significant improvement with both gold preparations compared to placebo for the number of tender joints, the joint tenderness score, and physician assessment of disease severity. GST was also significantly better than placebo for the joint swelling score. GST demonstrated more improvement in patients with anemia and thrombocytosis compared to the other treatment groups and both gold preparations were superior to placebo in improvement of an elevated erythrocyte sedimentation rate. Twenty-seven percent of patients on GST were withdrawn from the study for adverse drug reaction with rash and stomatitis being the predominant cause. Only 6% of patients on AUR were withdrawn for untoward drug effect. The time of onset of the adverse reactions is discussed. The two gold preparations were similar in efficacy although AUR was better tolerated.

Key words

Auranofin Gold Sodium Thiomalate Rheumatoid Arthritis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The Research Subcommittee of the Empire Rheumatism Council. Gold Therapy in Rheumatoid Arthritis: Report of a multi-centre controlled trial. Ann Rheum Dis 1960, 19, 95–117.CrossRefGoogle Scholar
  2. 2.
    The Cooperating Clinics Committee of the American Rheumatism Association.A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973, 16, 353–358.CrossRefGoogle Scholar
  3. 3.
    Sigler, J.W., Bluhm, G.B., Duncan, H., Sharp, J.T., Ensign, D.C., McCrum, W.R. Gold salts in the treatment of rheumatoid arthritis: A double-blind study. Ann Intern Med, 1974, 80, 21–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Schattenkirchner, M., Kaik, B., Muller-Fassbend-er, H., Rau, R., Zeidler, H. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study. J Rheumatol 1982, (Suppl 8), 9, 184–189.Google Scholar
  5. 5.
    Katz, W.A., Alexander, S., Bland, J.H., Blechman, W., Bluhm, G.B., Bonebrake, R.A., Falbo, A., Greenwald, R.A., Hartman, S., Hobbs, T., Indenbaum, S., Lergier, J.E., Lanier, B.G., Lightfoot, R.W. Jr., Phelps, P., Sheon, R.P., Torretti, D., Wenger, M.E., Wilske, K. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol 1982, (Suppl 8), 9, 173–178.Google Scholar
  6. 6.
    Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C., Boyce, E., Altz-Smith, M., Samuelson, CO., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1983, 26, 1303–1315.Google Scholar
  7. 7.
    Ropes, M.W., Bennett, G.A., Cobb, S., Jacox, R., Jessar, R.A. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958, 9, 175–176.PubMedGoogle Scholar
  8. 8.
    The Cooperating Clinics Committee of the American Rheumatism Association: A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965, 8, 302–334.CrossRefGoogle Scholar
  9. 9.
    Steinbrocker, O., Treager, C.H., Batterman, R.C. Therapeutic criteria in rheumatoid arthritis. J Amer Med Assoc 1949, 140, 659–662.CrossRefGoogle Scholar
  10. 10.
    Hutchinson, R.M., Davis, P., Jayson, M.I.V. Thrombocytosis in rheumatoid arthritis. Ann Rheum Dis 1976, 35, 138–142.PubMedCrossRefGoogle Scholar
  11. 11.
    Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C., Boyce, E., Altz-Smith, M., Samuelson, CO., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: Subsets of responders. J Rheumatol 1983, in press.Google Scholar
  12. 12.
    Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C, Boyce, E., Samuelson, CO., Altz-Smith, M., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: Response by treatment duration. Excerpta Medica 1983, 7, 115–132.Google Scholar
  13. 13.
    Williams, H.J., Ward, J.R., Egger, M.J., Reading, J.C, Altz-Smith, M., Samuelson, CO., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J. Comparison of oral and parenteral gold therapy and placebo in the treatment of rheumatoid arthritis. Scand J Rheumatol 1983, in press.Google Scholar
  14. 14.
    Srinivasan, R., Miller, B.L., Paulus, H.E. Longterm chrysotherapy in rheumatoid arthritis. Arthritis Rheum 1979, 22, 105–110.PubMedCrossRefGoogle Scholar
  15. 15.
    Flower, R.J., Moncada, S., Vane, J.R. Analgesic-antipyretics and anti-inflammatory agents; Drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics, 6th Edition. Editors: Gilman, A.G., Goodman, L.S., Gilman, A. New York, Macmillan Publishing Company, 1980, 715–716.Google Scholar
  16. 16.
    Menard, H.A., Beaudet, F., Davis, P., Harth, M., Percy, J.S., Russell, A.S., Thomson, J.M. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol 1982; (Suppl 8) 9, 179–183.Google Scholar
  17. 17.
    Bandilla, K., Gross, D., Gross, W., Herrlinger, J-D., Kriegel, W., Muller, W., Siegmeth, W., Tausch, G., Thumb, N., Wagenhauser, F.K. Oral gold therapy with auranofin (SK&F 39162). A multicenter open study in patients with rheumatoid arthritis. J Rheumatol 1982, (Suppl 8), 9, 154–159.Google Scholar
  18. 18.
    Kean, W.F., Anastassiades, T.P. Long term chrysotherapy. Incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum 1979, 22, 495–501.PubMedCrossRefGoogle Scholar
  19. 19.
    Penneys, N.S., Ackerman, A.B., Gottlieb, N.L. Gold dermatitis. A clinical and histopathological study. Arch Dermatol 1974, 109, 372–376.PubMedCrossRefGoogle Scholar
  20. 20.
    Stein, H.B., Urowitz, M.B. Gold induced enterocolitis: Case report and literature review. J Rheumatol 1976, 3, 21–26.PubMedGoogle Scholar
  21. 21.
    Berglof, F-E., Berglof, K., Walz, D.T. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol 1978, 5, 68–74.PubMedGoogle Scholar
  22. 22.
    Davis, P., Hughes, G.R.V. Significance of eosinophilia during gold therapy. Arthritis Rheum 1974, 17, 964–968.PubMedCrossRefGoogle Scholar
  23. 23.
    Gottlieb, N.L. Chrysotherapy. Bull Rheum Dis 1976-1977, 27, 912–917.PubMedGoogle Scholar
  24. 24.
    Coblyn, J.S., Weinblatt, M., Holdsworth, D., Glass, D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981, 95, 178–181.Google Scholar
  25. 25.
    Smith, P.R., Brown, G.M.M., Meyers, O.L. An open comparative study of auranofin vs gold sodium thiomalate. J Rheumatol 1982, (suppl 8) 9, 190–196.Google Scholar
  26. 26.
    Silverberg, D.S., Kidd, E.G., Shnitka, T.K., Ulan, R.A. Gold nephropathy. A clinical and pathologic study. Arthritis Rheum 1970, 13, 812–825.PubMedCrossRefGoogle Scholar
  27. 27.
    Favreau, M., Tannenbaum, H., Lough, J. Hepatic toxicity associated with gold therapy. Ann Intern Med 1977, 87, 717–719.PubMedCrossRefGoogle Scholar
  28. 28.
    Halla, J.T., Hardin, J.G., Linn, J.E. Postinjection nonvasomotor reactions during chrysotherapy. Constitutional and rheumatic symptoms following injections of gold salts. Arthritis Rheum 1977, 20, 1188–1191.PubMedCrossRefGoogle Scholar
  29. 29.
    Winterbauer, R.H., Wilske, K.R., Wheelis, R.F. Diffuse pulmonary injury associated with gold treatment. N Engl J Med 1976, 294, 919–921.PubMedCrossRefGoogle Scholar
  30. 30.
    Gould, P.W., McCormack, P.L., Palmer, D.G. Pulmonary damage associated with sodium aurothiomalate therapy. J Rheumatol 1977, 4, 252–260.PubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology 1984

Authors and Affiliations

  • H. J. Williams
    • 1
  • J. R. Ward
    • 1
  • M. J. Egger
    • 2
  • J. C. Reading
    • 2
  • C. O. Samuelson
    • 3
  • M. Altz-Smith
    • 4
  • R. W. Willkens
    • 5
  • M. A. Solsky
    • 6
  • S. P. Hayes
    • 7
  • D. Furst
    • 8
  • A. Weinstein
    • 9
  • R. F. Meenan
    • 10
  • M. Guttadauria
    • 11
  • S. B. Kaplan
    • 12
  • J. Klippel
    • 13
  1. 1.Department of MedicineUniversity of Utah school of MedicineSalt Lake City
  2. 2.Department of family and Community MedicineUniversity of Utah school of MedicineSalt Lake City
  3. 3.Division of RheumatologyUniversity of Utah school of MedicineSalt Lake City
  4. 4.Division of RheumatologyUniversity of Alabama in BirminghamBirmingham
  5. 5.Division of ArthritisHarborview Medical CenterSeattle
  6. 6.Arthritis Research UnitUniversity of MichiganAnn Arbor
  7. 7.Division of Immunology and RheumatologySchool of Medicine, University of Missouri-ColumbiaColumbia
  8. 8.Division of RheumatologyUniversity of California at Los AngelesLos Angeles
  9. 9.Division of Rheumatic DiseasesUniversity of ConnecticutFarmington
  10. 10.Arthritis SectionBoston University Medical CenterBoston
  11. 11.Department of MedicineState University of New York, Downstate Medical CenterBrooklyn
  12. 12.Department of MedicineUniversity of TennesseeMemphis
  13. 13.National Institute of ArthritisMetabolism and Digestive DiseasesBethesdaUSA

Personalised recommendations